|
Clinical and biological features
|
SSc (n: 33)
|
HD (n: 29)
|
P
|
|---|
|
Women, n (%)
|
29 (87.9)
|
23 (79.3)
|
ns
|
|
Age, median (range)
|
52 (30 to 80)
|
50 (18 to 68)
|
ns
|
|
Ethnicity: Caucasian (%)
|
30 (90)
|
29 (100)
|
ns
|
|
Diffuse cutaneous SSc, n (%)
|
20 (60.6)
|
N/A
| |
|
Age onset, mean (+/- SD)
|
44 (14)
|
N/A
| |
|
Disease duration, median (range)
|
7 (1 to 32)
|
N/A
| |
|
ANA positivity (%)
|
29 (87.9)
|
N/A
| |
|
ACA positivity (%)
|
4 (12.1)
|
N/A
| |
|
Anti-Scl70 positivity (%)
|
11 (33.3)
|
N/A
| |
|
Digital ulcers
|
19 (57.6)
|
N/A
| |
|
Calcinosis
|
9 (27.3)
|
N/A
| |
|
Arthritis
|
7 (21.2)
|
N/A
| |
|
PAH, n (%)
|
4 (12.1)
|
N/A
| |
|
ILD, n (%)
|
14 (42.4)
|
N/A
| |
|
Current immunosuppressive therapy (%)
|
0
|
N/A
| |
- ANA, anti-nuclear antibodies; ACA, anti-centromere antibodies; ILD, interstitial lung disease; PAH, pulmonary artery hypertension; N/A: not applicable. P as determined by the Fisher's exact test. ILD was observed on HRCT and confirmed by a TLC < 80% of the predicted value. Pre-capillary PAH was defined as a mean resting pulmonary artery pressure > 25 mmHg in presence of a pulmonary capillary wedge pressure £15 mmHg by a right heart catheterization.
